NCT00984711Unknown不适用
A Phase IV, Post-marketing, Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 150
- 试验地点
- 1
研究概览
简要总结
This study was designed to gather data regarding the efficacy and safety of Rituxan in clinical practice whereby patients may present with concomitant medical conditions, medications as well as varying presentations of rheumatoid arthritis not always captured within the "purer" population seen in an industry sponsored clinical trial.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with active rheumatoid arthritis as defined by ACR criteria
- •> 18 years of age at time of consent
- •Able to start RITUXAN therapy per the approved product monograph within approximately 30 days of confirmed enrollment
排除标准
- •Known Type 1 hypersensitivity or anaphylactic reactions to murine proteins, Chinese Hamster Ovary cell proteins or to any component of RITXAN as per approved Product monograph
- •Presence of any significant and or uncontrolled medical condition, which in the Investigator's opinion, precludes the use of RITUXAN as outlined in the Product Monograph
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Rituxan With or Without Methotrexate in Psoriatic ArthritisPsoriatic ArthritisNCT00509678Swedish Medical Center6
终止
1 期
Safety Study of Rituximab (Rituxan®) in Chronic UrticariaUrticariaNCT00216762Johns Hopkins University15
Unknown
2 期
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant MelanomaMalignant Melanoma of Skin Stage IIIMetastatic MelanomaNCT02142335California Cancer Assocaties for Research & Excellence17
终止
不适用
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular LymphomaLymphoma, FollicularNCT01609036Hoffmann-La Roche3
Unknown
2 期
Rituximab in Patients With Relapsed or Refractory TTP-HUSHemolytic Uremic SyndromeThrombotic Thrombocytopenic PurpuraNCT00531089Hamilton Health Sciences Corporation60